According to Wind data, as of August 3, a total of 104 A-share pharmaceutical biotechnology companies have disclosed their 2026 semi-annual performance forecasts. Looking at the maximum estimated net profit limit, 58 companies expect net profit to increase in the first half of this year. Of these, 28 expect net profit to mother to increase by more than 100% year on year. Analysts believe that the current focus of innovative drugs is the core focus. The market's quality requirements for authorized cooperation are becoming more and more strict, and more attention is being paid to the amount of money in the down payment, the strength of partners, and the solidity of clinical data. Pharmaceutical companies that can commercialize overseas with leading products and have the ability to continuously innovate will be more popular in the market.

According to Wind data, as of August 3, a total of 104 A-share pharmaceutical biotechnology companies have disclosed their 2026 semi-annual performance forecasts. Looking at the maximum estimated net profit limit, 58 companies expect net profit to increase in the first half of this year. Of these, 28 expect net profit to mother to increase by more than 100% year on year. Analysts believe that the current focus of innovative drugs is the core focus. The market's quality requirements for authorized cooperation are becoming more and more strict, and more attention is being paid to the amount of money in the down payment, the strength of partners, and the solidity of clinical data. Pharmaceutical companies that can commercialize overseas with leading products and have the ability to continuously innovate will be more popular in the market.